Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33,179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chinese guidelines for treatment of adult primary immune thrombocytopenia.
Liu XG, Bai XC, Chen FP, Cheng YF, Dai KS, Fang MY, Feng JM, Gong YP, Guo T, Guo XH, Han Y, Hong LJ, Hu Y, Hua BL, Huang RB, Li Y, Peng J, Shu MM, Sun J, Sun PY, Sun YQ, Wang CS, Wang SJ, Wang XM, Wu CM, Wu WM, Yan ZY, Yang FE, Yang LH, Yang RC, Yang TH, Ye X, Zhang GS, Zhang L, Zheng CC, Zhou H, Zhou M, Zhou RF, Zhou ZP, Zhu HL, Zhu TN, Hou M. Liu XG, et al. Among authors: zhou h, zhou zp, zhou rf, zhou m. Int J Hematol. 2018 Jun;107(6):615-623. doi: 10.1007/s12185-018-2445-z. Epub 2018 Apr 4. Int J Hematol. 2018. PMID: 29619624 Review.
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age.
Zhao P, Hou M, Liu Y, Liu HX, Huang RB, Yao HX, Niu T, Peng J, Jiang M, Han YQ, Hu JD, Zhou H, Zhou ZP, Qiu L, Zhang LS, Wang X, Wang HQ, Feng R, Yang LH, Ma LM, Wang SQ, Kong PY, Wang WS, Sun HP, Sun J, Zhou HB, Zhu TN, Wang LR, Zhang JY, Huang QS, Liu X, Fu HX, Li YY, Wang QF, Jiang Q, Jiang H, Lu J, Zhang XH. Zhao P, et al. Among authors: zhou h, zhou zp, zhou hb. Platelets. 2021 Jul 4;32(5):633-641. doi: 10.1080/09537104.2020.1786042. Epub 2020 Jul 2. Platelets. 2021. PMID: 32614630
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. Mei H, et al. Among authors: zhou h, zhou x. J Hematol Oncol. 2021 Feb 25;14(1):37. doi: 10.1186/s13045-021-01047-9. J Hematol Oncol. 2021. PMID: 33632264 Free PMC article. Clinical Trial.
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. Mei H, et al. Among authors: zhou h, zhou x. J Thromb Haemost. 2022 Mar;20(3):716-728. doi: 10.1111/jth.15602. Epub 2021 Dec 15. J Thromb Haemost. 2022. PMID: 34821020 Free article. Clinical Trial.
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.
Chong S, Zhao P, Huang RB, Zhou H, Zhang JN, Hou M, Liu Y, Yao HX, Niu T, Peng J, Jiang M, Han YQ, Hu JD, Zhou ZP, Qiu L, Zhang LS, Wang X, Wang HQ, Feng R, Yang LH, Ma LM, Wang SQ, Kong PY, Wang WS, Sun HP, Sun J, Zhou HB, Zhu TN, Wang LR, Zhang JY, Huang QS, Fu HX, Wu YJ, Li YY, Wang QF, Jiang Q, Jiang H, Lu J, Huang XJ, Zhang XH. Chong S, et al. Among authors: zhou h, zhou zp, zhou hb. Blood Adv. 2022 Jul 26;6(14):4320-4329. doi: 10.1182/bloodadvances.2022007226. Blood Adv. 2022. PMID: 35679462 Free PMC article.
2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy.
Zhang X, Chen F, Chen X, Cheng Y, Fang M, Feng J, Fu H, Gao H, Han Y, He A, Hou M, Hu Y, Huang R, Huang W, Jing Z, Kong P, Liang A, Liang M, Liu D, Liu J, Liu L, Liu X, Ma L, Mei H, Ni H, Niu T, Peng J, Qiao J, Ren J, Song Y, Tang LV, Tong T, Wang S, Wang X, Wang Z, Wei H, Wu D, Wu G, Xu C, Xu X, Xu Y, Yang L, Yang R, Yang T, Yin C, Yu L, Zhang G, Zhang L, Zhang L, Zhang X, Zhao W, Zhao Y, Zhou D, Zhou H, Zhou Z, Zhu T, Wang J, Huang X. Zhang X, et al. Among authors: zhou h, zhou z, zhou d. Chin Med J (Engl). 2022 Apr 20;135(8):887-889. doi: 10.1097/CM9.0000000000002043. Chin Med J (Engl). 2022. PMID: 35730369 Free PMC article. No abstract available.
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yu W, Jin J. Zhang Y, et al. Among authors: zhou h, zhou z. Am J Hematol. 2022 Dec;97(12):1510-1519. doi: 10.1002/ajh.26709. Epub 2022 Oct 4. Am J Hematol. 2022. PMID: 36054786 Free PMC article. Clinical Trial.
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.
Liu X, Zhou H, Hu Y, Yin J, Li J, Chen W, Huang R, Gong Y, Luo C, Mei H, Ding B, Gu C, Sun H, Leng Y, Ji D, Li Y, Yin H, Shi H, Chen K, Wang J, Fan S, Su W, Yang R. Liu X, et al. Among authors: zhou h. Lancet Haematol. 2023 Jun;10(6):e406-e418. doi: 10.1016/S2352-3026(23)00034-0. Epub 2023 Apr 4. Lancet Haematol. 2023. PMID: 37028433 Clinical Trial.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Zhang Y, Zhang Q, Liu Q, Dang H, Gao S, Wang W, Zhou H, Chen Y, Ma L, Wang J, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Tong H, Jin J. Zhang Y, et al. Among authors: zhou h. Am J Hematol. 2023 Oct;98(10):1579-1587. doi: 10.1002/ajh.27031. Epub 2023 Jul 19. Am J Hematol. 2023. PMID: 37466271 Clinical Trial.
33,179 results
You have reached the last available page of results. Please see the User Guide for more information.